{
    "nct_id": "NCT05052723",
    "official_title": "Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer",
    "inclusion_criteria": "* Diagnosis of pancreatic ductal adenocarcinoma\n* Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies\n* Patients must have adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation\n* Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation\n* Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy\n* Clinically significant cardiovascular disease\n* Uncontrolled hypertension\n* Inability to swallow tablets",
    "miscellaneous_criteria": ""
}